UNCY Stock Summary and Trading Ideas (Unicycive Therapeutics | NASDAQ:UNCY)

Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.

Unicycive Therapeutics trades on the NASDAQ stock market under the symbol UNCY.

As of September 4, 2026, UNCY stock price declined to $5.16 with 456,618 million shares trading.

UNCY has a beta of 0.78, meaning it tends to be less sensitive to market movements. UNCY has a correlation of 0.03 to the broad based SPY ETF.

UNCY has a market cap of $143.73 million. This is considered a Micro Cap stock.

Last quarter Unicycive Therapeutics reported $0 in Revenue and -$.06 earnings per share. This fell short of revenue expectation by $-29 million and exceeded earnings estimates by $.27.

In the last 3 years, UNCY traded as high as $18.18 and as low as $2.02.

The top ETF exchange traded funds that UNCY belongs to (by Net Assets): VTI, VXF, IWO, VTWO, DFAS.

UNCY has underperformed the market in the last year with a price return of +19.4% while the SPY ETF gained +19.8%. UNCY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -30.6% and -8.3%, respectively, while the SPY returned +2.0% and +0.6%, respectively.

UNCY support price is $5.14 and resistance is $5.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that UNCY shares will trade within this expected range on the day.